<DOC>
	<DOCNO>NCT02174159</DOCNO>
	<brief_summary>The study evaluate safety , tolerability , pharmacokinetics , antiretroviral activity single dose MK-8507 antiretroviral therapy ( ART ) -naive , HIV-1 infect participant . The hypothesis test study safe well-tolerated dose , MK-8507 superior antiretroviral activity historical placebo control , measure change baseline plasma HIV-1 ribonucleic acid ( RNA ) 168 hour postdose .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , Pharmacokinetics , Antiretroviral Activity MK-8507 Human Immunodeficiency Virus ( HIV-1 ) -Infected Participants ( MK-8507-003 )</brief_title>
	<detailed_description />
	<criteria>Male , nonpregnant nonbreastfeeding female , postmenopausal surgically sterile female ( confirm medical record , examination , laboratory test ) . Male participant female partner childbearing potential agrees use medically acceptable method contraception study 90 day receive study drug . Body mass index &lt; =35 kg/m^2 Other HIV infection , baseline health judge stable screening and/or prior administration study drug No clinicallysignificant electrocardiogram abnormality Documented HIV1 positive determine positive enzymelinked immunosorbent assay ( ELISA ) quantitative polymerase chain reaction ( PCR ) result confirmation Has screening plasma Cluster Differentiation ( CD4 ) Tcell count &gt; 200 /mm^3 Has plasma HIV1 RNA &gt; = 10,000 copies/mL within 30 day administration study drug ARTnaive , define never receive ART agent , receive &lt; =30 consecutive day investigational ART agent , exclude nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) , receive &lt; =60 consecutive day combination ART , exclude NNRTIs Has receive investigational agent license ART within 30 day study drug administration Diagnosed HIV1 infection &gt; =3 month screen Willing receive ART duration study Has evidence mutation confer resistance NNRTIs screen Mentally legally institutionalize incapacitated , significant emotional problem , history clinically significant psychiatric disorder History clinically significant stably control abnormality diseases History cancer , exception 1 ) adequatelytreated nonmelanomatous skin carcinoma carcinoma situ cervix , 2 ) malignancy successfully treat &gt; =10 year screen , 3 ) participant highly unlikely sustain recurrence duration study History significant multiple and/or severe allergy , anaphylactic reaction significant intolerability drug food Positive hepatitis B surface antigen History chronic hepatitis C virus ( HCV ) unless document cure negative HCV viral load Had major surgery , donate lose &gt; =1 unit ( ~500 mL ) blood within 4 week screen Participated another investigational trial within 4 week administration study drug Unable refrain anticipates use medication begin 4 week administration study drug throughout trial . Certain medication permit . Consumes &gt; 3 glass alcoholic beverage per day ( 1 glass equivalent 12 ounce beer , 4 ounce wine , 1 ounce distil spirit ) . Participants consume 4 glass alcoholic beverage per day may enrol discretion investigator . Consumes &gt; 10 cigarette per day unwilling restrict smoking &lt; =10 cigarette per day Regular user illicit drug history drug abuse ( include alcohol ) within 2 year Has immediate family member investigational site sponsor staff directly involve trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>